Skip to main content

Adipex-P Disease Interactions

There are 13 disease interactions with Adipex-P (phentermine).

Major

Amphetamines (applies to Adipex-P) cardiovascular

Major Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease, Hyperthyroidism, Cardiovascular Disease, Cerebral Vascular Disorder, History - Myocardial Infarction, History - Cerebrovascular Disease

Many amphetamines and amphetamine-like drugs are contraindicated in patients with advanced arteriosclerosis, symptomatic or unstable cardiac or cerebrovascular disease, moderate to severe hypertension, or hyperthyroidism. Like other sympathomimetic amines, amphetamines may cause cardiovascular adverse effects such as palpitation, tachycardia, cardiac arrhythmias, and elevation of blood pressure. Rarely, cardiomyopathy manifested as ventricular hypertrophy and/or congestive heart failure has been reported during chronic amphetamine use. In addition, sudden death has been reported in association with amphetamine therapy at usual dosages in children with structural cardiac abnormalities. In general, amphetamines should not be used in patients with structural cardiac abnormalities. If not otherwise contraindicated, therapy with amphetamines should be administered cautiously in patients with a current or past history of cardiovascular or cerebrovascular disease.

References

  1. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  2. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  3. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  4. "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim PROD (2001):
  5. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  6. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  7. "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc SUPPL-23 (2023):
  8. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
View all 8 references
Major

Amphetamines (applies to Adipex-P) glaucoma

Major Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

Some amphetamines and amphetamine-like drugs are contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles. Like other sympathomimetic amines, amphetamines can induce transient mydriasis. In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma. If possible, these agents should also be avoided in patients with other forms of glaucoma since mydriasis may occasionally increase intraocular pressure.

References

  1. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  2. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  3. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  4. "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim PROD (2001):
  5. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  6. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  7. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
  8. "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc SUPPL-23 (2023):
  9. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
View all 9 references
Major

CNS stimulants (applies to Adipex-P) agitation

Major Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, Neurosis, Anxiety/Stress

Some CNS stimulants are contraindicated in patients with marked agitation and/or anxiety since these symptoms may be aggravated. CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children. Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.

References

  1. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical PROD (2001):
  2. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals PROD (2001):
  3. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  4. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  5. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim PROD (2001):
  7. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  8. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  9. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  10. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
  11. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
View all 11 references
Major

CNS stimulants (applies to Adipex-P) cardiac disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease, Hypertension, Pheochromocytoma, Hyperthyroidism, Peripheral Arterial Disease

Many CNS stimulants are contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc. Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who are treated with CNS stimulants at the recommended dosages for attention deficit hyperactivity disorder; use of these agents should be avoided in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias, and other symptoms have been reported in adults under treatment. A careful assessment of the cardiovascular status should be done in patients being considered for treatment. This includes family history, physical exam, and further cardiac evaluation (EKG and echocardiogram). Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.

References

  1. "Product Information. Provigil (modafinil)." Cephalon, Inc PROD (2001):
  2. "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation PROD (2001):
  3. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  4. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  5. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  6. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  7. "Product Information. Concerta (methylphenidate)." Alza (2002):
  8. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
  9. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
  10. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
  11. "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
  12. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
  13. "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc SUPPL-38 (2023):
View all 13 references
Major

CNS stimulants (applies to Adipex-P) glaucoma

Major Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

The use of most CNS stimulants is contraindicated in patients with glaucoma, as these agents exhibit sympathomimetic activity and may induce mydriasis provoking an increase in intraocular pressure.

References

  1. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals PROD (2001):
  2. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  3. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  4. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  5. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  6. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
  7. "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
  8. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
View all 8 references
Major

CNS stimulants (applies to Adipex-P) hypertension

Major Potential Hazard, Moderate plausibility.

CNS stimulants increase blood pressure and heart rate; the use of some agents may be contraindicated in patients with severe/uncontrolled hypertension. Caution should be used when administering to patients with preexisting high blood pressure (even mild hypertension) and other cardiovascular conditions. All patients under treatment should be regularly monitored for potential tachycardia and hypertension.

References

  1. "Product Information. Provigil (modafinil)." Cephalon, Inc PROD (2001):
  2. "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation PROD (2001):
  3. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  4. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  5. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  6. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  7. "Product Information. Concerta (methylphenidate)." Alza (2002):
  8. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
  9. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
  10. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
  11. "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
  12. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
  13. "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc SUPPL-38 (2023):
View all 13 references
Major

CNS stimulants (applies to Adipex-P) psychiatric disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, Depression

The use of CNS stimulants can cause psychotic symptoms, suicidal ideation, and aggression, and can exacerbate symptoms of behavior disturbance and thought disorder; CNS stimulants may induce a manic or mixed episode in patients with bipolar disorder. Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders. All patients (particularly those with psychotic or bipolar disorders) should be monitored closely, especially during treatment initiation and at times of dose changes. Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder. Prior to initiating therapy, all patients should be screened for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or family history of suicide, bipolar disease, or depression). If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered. Some CNS stimulants are contraindicated in patients with marked agitation or anxiety.

References

  1. "Product Information. Provigil (modafinil)." Cephalon, Inc PROD (2001):
  2. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical PROD (2001):
  3. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals PROD (2001):
  4. "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation PROD (2001):
  5. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  6. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  7. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  8. "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim PROD (2001):
  9. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  10. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  11. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  12. "Product Information. Concerta (methylphenidate)." Alza (2002):
  13. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
  14. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
  15. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
  16. "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
  17. "Product Information. Fintepla (fenfluramine)." Zogenix, Inc (2020):
  18. "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc SUPPL-23 (2023):
  19. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
  20. "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc SUPPL-38 (2023):
View all 20 references
Major

CNS stimulants (applies to Adipex-P) pulmonary hypertension

Major Potential Hazard, Moderate plausibility. Applicable conditions: Valvular Heart Disease, Syncope

The use of some CNS stimulants has been associated with an increased risk of developing pulmonary hypertension, a rare but fatal disorder. The onset or aggravation of exertional dyspnea, or unexplained symptoms of angina pectoris, syncope, or lower extremity edema suggest the possibility of occurrence of pulmonary hypertension. Under these circumstances, treatment must be immediately discontinued, and the patient should be evaluated to confirm diagnosis. Caution should be exercised in patients with preexisting valvular heart disease or history of pulmonary hypertension. These drugs are not recommended in patients with known heart murmur or valvular heart disease.

References

  1. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  2. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  3. "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
  4. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
View all 4 references
Major

CNS stimulants (applies to Adipex-P) substance abuse

Major Potential Hazard, Moderate plausibility. Applicable conditions: Alcoholism, Drug Abuse/Dependence

CNS stimulants (especially amphetamines) have a high potential for abuse and misuse, which can lead to development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants can result in overdose and death; this risk is increased with higher doses or unapproved methods of administration (e.g., snorting, injection). Before prescribing a CNS stimulant, each patient's risk for abuse, misuse, and addiction should be assessed. Throughout therapy, it is recommended to reassess each patient's risk and frequently monitor for signs/symptoms of abuse, misuse, and addiction. Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse. The use of some agents is contraindicated in patients with a history of drug abuse.

References

  1. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical PROD (2001):
  2. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals PROD (2001):
  3. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  4. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  5. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim PROD (2001):
  7. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  8. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  9. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  10. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
  11. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
  12. "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc SUPPL-38 (2023):
View all 12 references
Moderate

CNS stimulants (applies to Adipex-P) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response. The dosage should be adjusted accordingly in certain agents.

References

  1. "Product Information. Provigil (modafinil)." Cephalon, Inc PROD (2001):
  2. "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation PROD (2001):
  3. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  4. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
  5. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
  6. "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc SUPPL-38 (2023):
View all 6 references
Moderate

Obesity drugs (applies to Adipex-P) diabetics

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Type 2

Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight. Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.

References

  1. "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company PROD (2001):
  2. "Product Information. Xenical (orlistat)." Roche Laboratories PROD (2001):
  3. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  4. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  5. "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim PROD (2001):
  6. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  7. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  8. "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc SUPPL-23 (2023):
  9. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
View all 9 references
Moderate

Phentermine (applies to Adipex-P) dialysis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: hemodialysis, peritoneal dialysis

Phentermine has not been studied in patients with end-stage renal disease on dialysis; therefore, this drug should be avoided in these patients.

References

  1. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
Moderate

Phentermine (applies to Adipex-P) liver disease

Moderate Potential Hazard, Moderate plausibility.

Phentermine may be partially metabolized in the liver. After a single dose of phentermine 15 mg-topiramate 92 mg, mean phentermine systemic exposure (AUC) was 37% and 60% higher in patients with mild (Child-Pugh score 5 to 6) and moderate (Child-Pugh score 7 to 9) liver dysfunction, respectively, compared to healthy subjects. No dosage adjustment is necessary in patients with mild liver dysfunction. In patients with moderate liver dysfunction, a reduction in the starting and/or maintenance dosage may be necessary in accordance with the individual manufacturer product information. Phentermine pharmacokinetics have not been studied in patients with severe liver dysfunction (Child-Pugh score 10 to 15); therefore, use should be avoided.

References

  1. "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc SUPPL-23 (2023):

Adipex-P drug interactions

There are 182 drug interactions with Adipex-P (phentermine).

Adipex-P alcohol/food interactions

There are 3 alcohol/food interactions with Adipex-P (phentermine).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.